Weekly issue 2026-W37 ·
Scoping Review on Polycystic Liver Disease in PKD1/PKD2 Gene Carriers: Genetic Aspects, Pathophysiology, and Therapeutic Approaches
Plain language
A review of 29 studies on polycystic liver disease in people with PKD1 or PKD2 variants explains why liver cysts can grow with kidney cysts, how genetics may relate to severity, and which treatments help selected patients with bothersome liver size. Somatostatin-type medicines remain the main drug approach discussed; other options such as mTOR inhibitors look mixed.
Clinical note
Scoping review (PRISMA; 29 studies, 2014–2024) on PLD in PKD1/PKD2 carriers. Maps genotype–phenotype links to hepatic cyst burden. Somatostatin analogues are the mainstay medical therapy for volume/symptoms in selected patients; mTOR inhibitors show modest/variable results. Synthesis/gap map — not a new RCT efficacy claim.
Question for your next visit
If my liver cysts cause discomfort or fullness, how do we decide whether I need a specialist assessment or treatment?